Drugs / velafermin
velafermin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00323518 | May 2006 → Aug 2008 | chemotherapy-induced oral mucositis | CuraGen Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00104065 | Jan → Dec 2005 | chemotherapy-induced oral mucositis | CuraGen Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | velafermin | “CG53135-05, velafermin” NCT00104065 ↗ |
| Known as | CG53135-05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00104065 ↗ |
| Known as | Velafermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108059 ↗ |
| Known as | Velafermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108059 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant human fibroblast growth factor-20 (rhFGF-20) protein” NCT00104065 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT00104065 ↗ |